m+Medelevator.RU
← Поиск публикаций
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025

Clinical Characteristics and Treatment Outcomes in Patients With Incomplete Microscopic Colitis: Consideration for Expanding the Definition of Microscopic Colitis.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Tome June, Bauss Jacob M, Harmsen William S, Khanna Sahil, Graham Rondell P, Pardi Darrell S

Аннотация

BACKGROUND & AIMS: Incomplete microscopic colitis (MCi) is inadequately characterized and does not meet the histologic criteria for microscopic colitis (MC). The clinical features, treatment outcomes, and rates of recurrence are not well-known. The objective of this study was to assess these features.

METHODS: Adults with chronic watery diarrhea diagnosed with MCi on histology (2010-2023) at Mayo Clinic were identified. Response at 12 ± 4 weeks after treatment initiation was defined as: complete (resolution of diarrhea), partial (≥50% improvement), nonresponse (<50% improvement), or intolerance (withdrawal due to adverse effects). Logistic and Cox regression were used to identify predictors of nonresponse and risk of recurrence.

RESULTS: A total of 204 patients were identified (median age, 62 years [range, 22-90 years]; 66.2% women) with median follow-up of 3.1 years (range, 0.4-13.3) years. Most (80.4%) were on drugs commonly implicated in MC; 6.8% had improvement after discontinuation of associated culprit medications alone. Patients were treated with the following: 37.3% loperamide, 28.4% budesonide, 18.6% bismuth subsalicylate, 7.4% bile acid sequestrant, and 1.5% other medications. Clinical outcomes were: 72.6% complete response, 22.1% partial response, 3.4% nonresponse, and 1.9.% intolerance. There were no differences in outcomes between MCi subtypes (P = .11). Fecal incontinence was the only predictor of nonresponse. After discontinuation of therapy, 35.8% had recurrence, and 13.7% developed MC.

CONCLUSIONS: In one of the largest cohorts of MCi, the majority were on drugs implicated in MC and almost three-fourths had a complete response to therapy including budesonide. Given the commonalities with MC, the histologic definition should potentially be expanded to include these patients.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты